KP Therapeutics (Europe)
Innovation
Innovation is the backbone of our company and also fuels our daily goal to shape the future in health as we help overcome global challenges. Our scientific team is doing their utmost in developing medicines that perform well. With our innovative solutions, we are responding to the global challenges in healthcare.
We concentrate our efforts on a core set of therapeutic areas where we feel we can have an even greater impact on disease. By researching areas of medicine where we can help foster more advanced techniques, we are supporting our colleagues in medicine.
Our Research
From Theory to Reality
GA100/GA101:
Precision Therapeutic approach for the treatment of brain cancers.
GA100/GA101: Are precision magnetic resonance imaging (MRI) contrast agents for the early detection of ovarian, breast and prostate cancer primary and metastatic lesions by MRI.6 GA100/GA101 can also be adapted as smart theranostic nanoparticles that simultaneously deliver contrast agent and anti-cancer drugs to primary and metastatic tumours under the influence of MR guided focused ultrasound (MRgFUS) irradiation. KPT Europe has launched a joint venture in the USA (VJV) to develop a GA100/101-based PTA for the treatment of brain cancers
GA9/LITA
Precision Therapeutic approaches for the treatment of brain cancers and metabolic syndrome.
GA9/LITA (liposome encapsulated acetate): Liver-targeted precision nanomedicine for the management of metabolic syndrome. Targeted delivery of LITA nanoparticles to cancer cells also results in selective lethality of cancer cells, leaving normal cells unharmed. As part of its joint venture in the USA (VJV), KPT Europe wishes to develop a GA9/LITA-based PTA for the treatment of brain cancers. KPT Europe is also looking for financial support to develop a LITA-based PTA to end of phase 2a clinical trials within 3 years for the treatment of non-alcoholic steatohepatitis (NASH),7 thereafter the company will seek to recapitalize or work with a pharma/biotech partner to complete phase 3 clinical trials and market authorisation.
GA7:
Precision Therapeutic approach for the treatment of COVID-19.
GA7: A bioactive thio-ether fatty acid (THEFA) family demonstrated to have important anti-inflammatory properties in the treatment of metabolic syndrome. Key FDA/EMA approved drugs have been found potent anti-COVID-19 drugs in very recent HTS experiments in South Korea, namely niclosamide, ciclesonide, nafamostate mesylate and camostat mesylate. KPT Europe plans a GA7-based PTA for per oral and intranasal delivery of these medically essential drugs to optimize their bioavailability at target cells. KPT Europe is looking for financial support to develop the most effective of these GA7-based PTAs to end of phase 1 clinical trials in healthy volunteers, after which the company intends either to re-capitalize or work with either a large pharma or biotech partner to complete phase 2/3 clinical trials for market authorisation. GA7-based PTAs should be adaptable for use with other known and novel drugs against future zoonotic virus infections.
GA8:
A precision therapeutic agent for the treatment of refractory epilepsy and pain.
GA8: A precision therapeutic agent for the treatment of refractory epilepsy and pain. The GA8-based PTA is based upon well-defined target cells, ease of access/guidance to target, and prolonged, measurable treatment effects. KPT Europe is expecting to develop GA8-based PTAs to end of phase 2a clinical trials in paediatric & adolescent epilepsy as fast track to market indication, after which the company will either re-capitalize or work with either a large pharma or biotech partner to complete phase 3 clinical trials for market authorisation. Although our primary target indication is epilepsy, a GA8-based PTA can also be implemented for the treatment of nociceptive pain (e.g. pain that covers most leg, arm, and back pain) which is the most common type of pain that people experience. Since the GA8-based PTA treats pain where it originates in the periphery, and not in the central nervous system, then our GA8-based PTA offers an exceptional opportunity to develop a truly non-addictive, non-opioid approach for the treatment of chronic pain.
GA5:
Precision Therapeutic approaches for the treatment of major liver disorders.
Precision Therapeutic approaches for the treatment of major liver disorders.
GA5: A precision nanomedicine for the targeted delivery of therapeutic RNAs to target cells in the liver. Two primary applications involve delivery of therapeutic siRNAs or mRNAs to target cells for the treatment of chronic hepatitis B virus (CHB) infections and hepatocellular carcinoma (HCC). KPT Europe expects to develop GA5-based PTAs for such liver diseases as a key component of its anticipated South Korea-based JV activities (see above)
Partnerships
The global precision medicine market including nanomedicines is expected to register 12.48% compound annual growth rate (CAGR) and is anticipated to reach $126.14 billion by 2025. Precision medicine, in general, is now one of the most modernized trends in the healthcare industry, which has shown a tremendous level of progress in the last few years. KPT Europe is aiming to become a leading player in this market. Accordingly, KPT Europe represents a ground-breaking, pharmaceutical & biotechnology investment opportunity with tremendous potential returns on investment. This will be realized going forward either by trade sale, product sale and/or by initial public offering (IPO).
KPT Europe has a clear pipeline of novel precision nanomedicines and therapeutic agents. This pipeline is being developed within KPT Europe or through joint ventures (JVs).
KPT Europe has launched a joint venture in the USA (VJV) to develop GA100/101-based and GA9/LITA PTAs for the treatment of brain cancers.
KPT Europe expects to develop GA5-based PTAs for such liver diseases as a key component of its anticipated South Korea-based JV activities (anticipated launch early 2021)
KPT Europe combines a unique blend of highly successful entrepreneurs, technology business founders and corporate executives with a strong scientific pedigree, plus extensive offshore experience and networks. These skill sets make KPT Europe well suited to supporting and mentoring entrepreneurial management to help drive growth and create value while leveraging collective experience to reduce risk and enhance returns for investors.